Back to Awarded Treatment Trials
Awarded Trial: 03T-315
Grant ID
03T-315
Illness
Prodromal Psychosis
Primary Drug/Intervention
Ethyl Eicosapentanoic Acid
Primary Dosage
2g
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Amminger
Sample Size
80
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
PACE criteria for ARMS, PANSS, MADRS, GAF, Conversion to psychosis
Results
Eighty one patients, aged 13 to 24, who were considered to be at high risk for psychosis were randomized. High risk patients met operationalized definitions for "attenuated psychotic symptoms", "transient psychosis", or "genetic risk plus decrease in functioning". The cumulative rate of conversion to psychosis at 3 months was 2.4% for the omega-3 group and 20.0% for the placebo group. This difference seemed to be maintained at 6 and 12 months of follow-up.
Publication
Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67(2):146-154. Amminger GP, McGorry PD. Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology. 2012 Jan;37(1):309-10.
Link
http://www.ncbi.nlm.nih.gov/pubmed/20124114; http://www.ncbi.nlm.nih.gov/pubmed/22157875
PI Name
G. Amminger
Degree
MD
Center
Department of Child and Adolescent Neuro-Psychiatry
Institution
University of Vienna
Address
Waehringer Guertel 18-20
City or Town
Vienna
State or Province
N/A
Zip or Postal Code
1090
Country
Austria
Email Address
paul.amminger@meduniwien.ac.at